These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 24260981)
21. Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11. Hoffmann HJ; Nielsen LP; Harving H; Heinig JH; Dahl R Clin Respir J; 2008 Jul; 2(3):149-57. PubMed ID: 20298323 [TBL] [Abstract][Full Text] [Related]
22. Effect of inhaled steroid therapy on exhaled nitric oxide and bronchial responsiveness in children with asthma. Nishio K; Odajima H; Motomura C; Nakao F; Nishima S J Asthma; 2006 Dec; 43(10):739-43. PubMed ID: 17169825 [TBL] [Abstract][Full Text] [Related]
23. Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma. Boulet LP; Turcotte H; Prince P; Lemière C; Olivenstein R; Laprise C; Larivée P; Bégin P; Laviolette M Respir Med; 2009 Oct; 103(10):1554-63. PubMed ID: 19692221 [TBL] [Abstract][Full Text] [Related]
24. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715 [TBL] [Abstract][Full Text] [Related]
25. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. van den Berge M; Luijk B; Bareille P; Dallow N; Postma DS; Lammers JW Allergy; 2010 Dec; 65(12):1531-5. PubMed ID: 20560909 [TBL] [Abstract][Full Text] [Related]
26. Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma. Hozawa S; Haruta Y; Terada M; Yamakido M Allergol Int; 2009 Dec; 58(4):509-18. PubMed ID: 19700936 [TBL] [Abstract][Full Text] [Related]
27. Studies of the effects of inhaled magnesium on airway reactivity to histamine and adenosine monophosphate in asthmatic subjects. Hill J; Lewis S; Britton J Clin Exp Allergy; 1997 May; 27(5):546-51. PubMed ID: 9179429 [TBL] [Abstract][Full Text] [Related]
29. Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing. Ulrik CS; Diamant Z Clin Exp Allergy; 2010 Apr; 40(4):576-81. PubMed ID: 20128823 [TBL] [Abstract][Full Text] [Related]
30. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. Nelson HS; Busse WW; Kerwin E; Church N; Emmett A; Rickard K; Knobil K J Allergy Clin Immunol; 2000 Dec; 106(6):1088-95. PubMed ID: 11112891 [TBL] [Abstract][Full Text] [Related]
31. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Dijkstra A; Vonk JM; Jongepier H; Koppelman GH; Schouten JP; ten Hacken NH; Timens W; Postma DS Thorax; 2006 Feb; 61(2):105-10. PubMed ID: 16308336 [TBL] [Abstract][Full Text] [Related]
32. Determinants of airway responsiveness to adenosine 5'-monophosphate in school-age children with asthma. Bakirtas A; Turktas I Pediatr Pulmonol; 2006 Jun; 41(6):515-21. PubMed ID: 16617445 [TBL] [Abstract][Full Text] [Related]
33. Perception of airway narrowing during reduction of inhaled corticosteroids and asthma exacerbation. Salome CM; Leuppi JD; Freed R; Marks GB Thorax; 2003 Dec; 58(12):1042-7. PubMed ID: 14645970 [TBL] [Abstract][Full Text] [Related]
34. Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. Fardon TC; Lee DK; Hodge MR; Lipworth BJ Ann Allergy Asthma Immunol; 2005 Sep; 95(3):259-65. PubMed ID: 16200817 [TBL] [Abstract][Full Text] [Related]
35. [Prospective observational study of clinical course after stopping inhaled corticosteroids in child asthma]. Akasawa A; Suda T; Akashi M; Narita M; Ohya Y; Manki A; Watanabe H; Kumaki M; Matsumoto K; Saito H Arerugi; 2009 Oct; 58(10):1407-17. PubMed ID: 19901510 [TBL] [Abstract][Full Text] [Related]
36. Variability of methacholine bronchoprovocation and the effect of inhaled corticosteroids in mild asthma. Sumino K; Sugar EA; Irvin CG; Kaminsky DA; Shade D; Wei CY; Holbrook JT; Wise RA; Castro M; Ann Allergy Asthma Immunol; 2014 Apr; 112(4):354-60.e1. PubMed ID: 24507830 [TBL] [Abstract][Full Text] [Related]
37. Five-year changes in airflow obstruction and airway responsiveness in mild to moderate asthma. Boulet LP; Jobin C; Milot J; Turcotte H Clin Invest Med; 1994 Oct; 17(5):432-42. PubMed ID: 7867248 [TBL] [Abstract][Full Text] [Related]
38. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Lötvall J; Bateman ED; Bleecker ER; Busse WW; Woodcock A; Follows R; Lim J; Stone S; Jacques L; Haumann B Eur Respir J; 2012 Sep; 40(3):570-9. PubMed ID: 22362859 [TBL] [Abstract][Full Text] [Related]
39. The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. Hagan JB; Samant SA; Volcheck GW; Li JT; Hagan CR; Erwin PJ; Rank MA Allergy; 2014 Apr; 69(4):510-6. PubMed ID: 24571355 [TBL] [Abstract][Full Text] [Related]
40. Stepping down from combination asthma therapy: The predictors of outcome. Koskela HO; Purokivi MK; Kokkarinen J Respir Med; 2016 Aug; 117():109-15. PubMed ID: 27492520 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]